Fundraising FoxPike Therapeutics
Vancouver, US · Founded 2019 · British Columbia, Canada corporation
Find your way into Pike Therapeutics
Sign up to see every warm intro you have to Pike Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pike Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Pike develops a multi-day, continuous-delivery patch formulation of dronabinol to address non-motor symptoms in Parkinson's Disease and agitation in Alzheimer's and dementia patients.
Founders & leadership
IF
IAN FODIECHIEF FINANCIAL OFFICER, SECRETARYIan Fodie has over 30 years of experience in small to medium-sized businesses with international operations in intangible and real property, including more than 20 years in public company roles. He has served as a board member focused on corporate governance and financing.
BM
BRADLEY MILESCHIEF EXECUTIVE OFFICER
Board
MP
MARK PURDYBoard director
Reported raises · per SEC filings
Form D private placements$1M disclosed across 3 rounds · 2021–2026
▶$760KraisedJul 2026 · 5 investors · Other TechnologyRule 506(b)
▶$760KraisedJul 2026 · 5 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- IAN FODIEExecutive Officer, Director
- BRADLEY MILESExecutive Officer, Director
- MARK PURDYDirector
- Offering amount
- $760K
- Amount sold
- $760K
- First sale
- Jun 2026
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$100KraisedSep 2023 · 2 investors · Other TechnologyRule 506(b)
▶$100KraisedSep 2023 · 2 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- MARK PURDYDirector
- IAN FODIEExecutive Officer, Director
- BRADLEY MILESExecutive Officer, Director
- Offering amount
- $100K
- Amount sold
- $100K
- First sale
- Aug 2023
- Incorporated
- Corporation, British Columbia, Canada, 2019
- Federal exemptions
- 06b
▶$175KraisedSep 2021 · 4 investors · Other TechnologyRule 506(b)
▶$175KraisedSep 2021 · 4 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- MARK PURDYDirector
- IAN FODIEExecutive Officer, Director
- BRADLEY MILESExecutive Officer, Director
- Offering amount
- $175K
- Amount sold
- $175K
- First sale
- Aug 2021
- Incorporated
- Corporation, British Columbia, Canada, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Pike Therapeutics do?
- Pike develops a multi-day, continuous-delivery patch formulation of dronabinol to address non-motor symptoms in Parkinson's Disease and agitation in Alzheimer's and dementia patients.
- How much funding has Pike Therapeutics raised?
- Pike Therapeutics has disclosed $1M raised across 3 rounds.
- Where is Pike Therapeutics headquartered?
- Pike Therapeutics is headquartered in Vancouver, US.